In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Janus kinase (JAK) inhibitor'
Please login to view adverse reactions.
- (2023): Mok CC+, Rheumatology (Oxford) May, Online ahead of print
- (2020): Olivera P+, Gastroenterology Jan, Epub ahead of print [REVIEW]
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2025): Di Napoli R+, Drug Saf Mar, Online ahead of print14% (pharmacovigilance / pharmacoepidemiology)
- (2025): Nam W+, Int J Clin Pharmacol Ther Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2024): Goldman A+, Semin Arthritis Rheum May, Online ahead of print (association) (pharmacovigilance / pharmacoepidemiology)
- Negative findings
- (2023): Wei Q+, Front Pharmacol Aug (e-Collection) [REVIEW] (no evidence of increased risk of major adverse cardiovascular events (MACE) )
- (2025): Nam W+, Int J Clin Pharmacol Ther Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2020): Rajasimhan S+, Drugs Aging Jun, Online ahead of print [REVIEW]
- (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]
- (2024): Farkas B+, J Clin Med 13(24), 780410%
- (2021): Ng A, Eur J Gastroenterol Hepatol 33(1S Suppl 1), e1090
Gastrointestinal disorder / discomfort
- (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]
- (2024): Martinez de la Torre A+, Drug Saf Nov, Online ahead of print (association) (WHO pharmacovigilance database) (pharmacovigilance / pharmacoepidemiology)
- (2022): Chen J+, J Am Acad Dermatol Mar, Online ahead of print [REVIEW]
- (2017): Shreberk-Hassidim R+, J Am Acad Dermatol 76(4), 745 [REVIEW]
Upper respiratory tract infection
- (2021): Gómez-Arias PJ+, Dermatol Ther (Heidelb) Apr, Online ahead of print [REVIEW]
- (2017): Shreberk-Hassidim R+, J Am Acad Dermatol 76(4), 745 [REVIEW]
Adverse effects / adverse reactions
- (2025): Konzett V+, Ann Rheum Dis Feb, Online ahead of print [REVIEW]
- (2025): Mikaeili B+, Clin Rheumatol Feb, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
- (2024): Strunz PP+, Front Immunol Aug (e-Collection) [REVIEW]
- (2024): Szekanecz Z+, Nat Rev Rheumatol Jan, Online ahead of print [REVIEW]
- (2023): Singh JA, BioDrugs Jun, Online ahead of print [REVIEW]
- (2023): Yang F+, Clin Rheumatol Feb, Online ahead of print [REVIEW]
- (2022): Alves C+, Eur J Clin Pharmacol Oct, Online ahead of print [REVIEW]
- (2022): Daniele S+, J Drugs Dermatol 21(12), 1298-1303 [REVIEW]
- (2022): Elmariah SB+, Am J Clin Dermatol Jun, Online ahead of print [REVIEW]
- (2022): Fleischmann R, Expert Rev Clin Immunol Feb, Online ahead of print [REVIEW]
- (2022): Shalabi MMK+, Skin Therapy Lett 27(1), 4-9 [REVIEW]
- (2021): Wood H+, Int J Dermatol Aug, Online ahead of print [REVIEW]
